Significantly Expands Business Development and Scientific Capabilities
BEDMINSTER, N.J., May 7 /PRNewswire-FirstCall/ --
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, announced today the hiring of two senior
level executives. Chris Pugh has been named Vice President, Business
Development and Eric Mishkin, Ph.D., has been named Senior Vice President and
Chief Scientific Officer.
Chris Pugh has more than ten years of product and business development
experience. Most recently, he was Director of Business Development for
Guilford Pharmaceuticals. Prior to Guilford, Mr. Pugh was Project Manager for
the Vaccine Division of Merck & Co., and has been employed as Group Product
Manager at SmithKline Beecham (now GlaxoSmithKline). Mr. Pugh holds a CNAA
Master of Science degree in Biotechnology which included bench research at the
University of Cambridge (Institute of Biotechnology). His undergraduate
degree is a joint B.Sc. degree in Zoology and Psychology from University
College Swan, United Kingdom.
"Chris Pugh has an exceptionally solid combination of industry experience
and scientific training," said Jim O'Shea, Chairman, President and CEO. "His
expertise will help the Company continue to expand its business development
efforts as we continue to explore opportunities for our technology in the
biotechnology and pharmaceutical industries."
Eric Mishkin, Ph.D., has twenty-five years of experience in immunology
research and microbiology. His recent position was Director of Immunology
Research at Wyeth-Ayerst. Prior to Wyeth-Ayerst, Dr. Mishkin was the
Principal Research Immunologist for Viral Vaccine Immunobiology. He has also
been employed as the Principal Research Immunologist and a Research
Microbiologist for the Department of Viral Vaccine Research and Development,
Lederle-Praxis Biologicals in Pearl River, New York. Dr. Mishkin holds a
Ph.D. in Parasitology and a M.S. degree in Zoology from the University of
Connecticut and a B.A. degree in Biology from Hofstra University.
"Dr. Mishkin's experience in the vanguard of vaccine research and
extraordinary talent in immunology research and microbiology allows us to
broaden the Company's clinical research capabilities into new relevant
applications for our technology," commented O'Shea.
Mr. Pugh and Dr. Mishkin will be based in Bedminster, New Jersey, at
Bioject's new corporate office which opened in April 2002. The Company's
manufacturing and engineering operations will remain in Portland, Oregon.
About Bioject
Bioject Medical Technologies Inc., based in Bedminster, New Jersey with
manufacturing facilities in Portland, Oregon, is an innovative developer and
manufacturer of needle-free drug delivery systems. Needle-free injection
works by forcing medication at high speed through a tiny orifice held against
the skin. This creates a fine stream of high-pressure fluid penetrating the
skin and depositing medication in the tissue beneath. Bioject's strategic
partners include Serono and Alkermes.
Corporate Headquarters:
Bioject Medical Technologies Inc.
211 Somerville Road (Route 202 North)
Bedminster, NJ 07921
908-470-2800
Manufacturing Operations:
Bioject Medical Technologies Inc.
7620 S.W. Bridgeport Road
Portland, OR 97224
503-639-7221
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Readers of this press release are referred to the Company's
filings with the Securities and Exchange Commission, including the Company's
reports on Forms 10-K and Forms 10-Q for further discussions of factors that
could affect future results. Forward-looking statements are based on the
estimates and opinions of management on the date the statements are made. The
Company assumes no obligation to update forward-looking statements if
conditions or management's estimates or opinions should change.
For more information about Bioject, visit http://www.bioject.com.
SOURCE Bioject Medical Technologies, Inc.
 back to top
Related links:
http://www.bioject.com
Company News On-Call:
http://www.prnewswire.com/comp/101750.html
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies, Inc., +1-908-470-2800, ext.
5103, or cheer@bioject.com
|
